Arcus Biosciences Inc (NYSE:RCUS)
$ 15.27 -0.56 (-3.54%) Market Cap: 1.40 Bil Enterprise Value: 417.63 Mil PE Ratio: 0 PB Ratio: 2.47 GF Score: 79/100

Arcus Biosciences Inc at Morgan Stanley Global Healthcare Conference Transcript

Sep 12, 2023 / 08:15PM GMT
Release Date Price: $21.25 (+2.21%)
Terence C. Flynn
Morgan Stanley, Research Division - Equity Analyst

All right. Well, thanks so much, everyone, for joining us. I'm Terence Flynn, the U.S. biopharma analyst here at Morgan Stanley, and we're very pleased to have Arcus with us this afternoon. We have Terry Rosen, the company's CEO; and Jen Jarrett, the company's COO. Thank you both for being here.

Before we get started, please see Morgan Stanley's research disclosure website at www.morganstanley.com/researchdisclosures. If you have any questions, please reach out to your Morgan Stanley sales representative.

Questions & Answers

Terence C. Flynn
Morgan Stanley, Research Division - Equity Analyst

Well, again, thank you both for being here. I thought one place we'd start would be just high-level, obviously, the Gilead collaboration has been very important for the company as we think about what it's allowed you to do in terms of kind of parallel process opportunities, strength of balance

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot